No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NKTR Nektar Therapeutics
- 1.3500
- -0.1400-9.40%
Close Apr 17 16:00 ET
- 1.3000
- -0.0500-3.70%
Post 19:58 ET
247.88MMarket Cap-931P/E (TTM)
1.5000High1.2800Low3.26MVolume1.4800Open1.4900Pre Close4.47MTurnover2.00%Turnover RatioLossP/E (Static)183.62MShares1.750052wk High1.89P/B220.19MFloat Cap0.412652wk Low--Dividend TTM163.11MShs Float111.3600Historical High--Div YieldTTM14.77%Amplitude0.4126Historical Low1.3690Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq
Express News | Nektar Therapeutics Shares Hit Session Low With Volume Pickup, Last Down 8.4% at $1.53
NKTR, VERU and EGIO Among Mid-day Movers
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersRallybio (NASDAQ:RLYB) shares moved upwards by 70.5% to $2.78 during Thursday's regular session. The company's market cap stands at $105.1 million. Eliem Therapeutics (NASDAQ:ELYM) shares rose
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual
Comments
Update
$Nektar Therapeutics(NKTR.US$ Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq
1
A Bio research company with these financials but trading this low! How sad
$Nektar Therapeutics(NKTR.US$ • Nektar Therapeutics has regained full rights to its drug candidate REZPEG and is advancing Phase 2b studies for atopic dermatitis and alopecia areata.
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
1
Nektar Therapeutics' CEO, Howard Robin, is pleased with the deal, stating it strengthens the company's finances and extends its cash runway to Q3 2026. He also emphasized the potential of rezpegaldesleukin, a novel biologic in Phase 2b studies.
Update
$Nektar Therapeutics(NKTR.US$ Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg